CASI News & Events

Casi Pharmaceuticals announced that it has received a determination letter from the hearings panel of the Nasdaq Stock Market dated February 23, notifying the company that the panel determined to delist the company's securities from Nasdaq, due to the company's failure to satisfy the continued listing conditions as previously disclosed. As a result, the company securities will be suspended from trading at the open of business on February 26, and delisted from Nasdaq after the completion of certain applicable process. The company does not intend to request a review of such decision. Following the delisting, the company expects that its ordinary shares will be quoted on the "over the counter" market operated by OTC Markets Group Inc. so that a trading market may continue to exist for its ordinary shares. The delisting from Nasdaq will have no significant impact on the company's operations.

CASI Pharmaceuticals received a determination letter from the Hearings Panel of The Nasdaq Stock Market dated February 23, 2026, notifying the Company that the Panel determined to delist the Company's securities from Nasdaq, due to the Company's failure to satisfy the continued listing conditions as previously disclosed. As a result, the Company securities will be suspended from trading at the open of business on February 26, 2026, and delisted from Nasdaq after the completion of certain applicable process. The Company does not intend to request a review of such decision.Following the delisting, the Company expects that its ordinary shares will be quoted on the "over the counter" market operated by OTC Markets Group so that a trading market may continue to exist for its ordinary shares.

CASI Pharmaceuticals announced that China National Medical Products Administration has approved a Clinical Trial Application to conduct a Phase 1 /2 clinical trial for CID-103 in adults with chronic active renal allograft antibody-mediated rejection. The Phase 1 / 2 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of CID-103 in patients with renal allograft AMR.